<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Iproplatin (cis-dichloro-transdihydroxybis-<z:chebi fb="0" ids="15739">isopropylamine</z:chebi> <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> IV; CHIP) is a second generation <z:chebi fb="2" ids="27899">cisplatin</z:chebi> derivative that was developed to retain the <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> effect of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> with fewer toxic effects </plain></SENT>
<SENT sid="1" pm="."><plain>Early clinical studies showed moderate activity in some <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, with disappointing results in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the lower gastrointestinal tract </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> was the dose-limiting toxic effect in the <z:hpo ids='HP_0011009'>acute</z:hpo> setting </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The authors report a patient with metastatic <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the colon who received long-term therapy with CHIP </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The patient achieved complete remission of disease after prolonged treatment with CHIP </plain></SENT>
<SENT sid="5" pm="."><plain>The patient subsequently had a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> that rapidly transformed to <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0002488'>Acute leukemia</z:hpo> may represent a late complication of CHIP therapy </plain></SENT>
</text></document>